Results of transrectal focussed ultrasound for the treatment of localized prostate cancer (120 patients with PSA ≤ 10 ng/ml);Résultats du traitement par ultrasons focalisés transrectaux du cancer localisé de la prostate (120 patients avec PSA ≤ à 10 ng/ml)

Progres en Urologie

Volumn 13, Issue 1, 2003, Pages 60-72

  Poissonnier, Laura ^a   Gelet, Albert ^a   Chapelon, Jean Yves ^b   Bouvier, Raymonde ^a   Rouviere, Olivier ^a   Pangaud, Catherine ^a   Lyonnet, Denis ^a   Dubernard, Jean Michel ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Cancer; Focussed ultrasounds; Prostate; Treatment

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CALCULATION; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; EVALUATION; FOLLOW UP; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; KAPLAN MEIER METHOD; LABORATORY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; POPULATION; PROSTATE CANCER; PROSTATECTOMY; RECTUM; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; TREATMENT FAILURE; TUMOR BIOPSY; BLOOD; CANCER STAGING; HISTOLOGY; INSTRUMENTATION; METHODOLOGY; PATHOLOGY; PROSTATE; PROSTATE TUMOR;

AGED; HUMANS; MALE; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 0041804456     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. ARTERBERY V.E., WALLNER K., ROY J., FUKS Z. : Short-term morbidity from CT-planned transperineal I-125 prostate implants. Int J. Radiat. Oncol. Biol. Phys., 1993 ; 25 : 661-667.
2. BAGSHAW M.A., COX R.S., RAY G.R. : Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr., 1988 ; 7 : 47-60.
3. BANKER F.L. : The preservation of potency after external beam irradiation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1988 ; 15 : 219-220.
4. BEARD C.J., LAMB C., BUSWELL L., SCHNEIDER L., PROPERT K.J., GLADSTONE D., D'AMICO A., KAPLAN I. : Radiation-associated morbidity in patients undergoing small-field external beam irradiation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1998 ; 41 : 257-262.
5. BENOIT R.M., NASLUND M.J., COHEN J.K. : A comparison of complications between ultrasound-guided prostate brachytherapy and open prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 47 : 909-913.
6. BENOIT R.M., NASLUND M.J., COHEN J.K. : Complications after prostate brachytherapy in the medicare population. Urology 2000 ; 55 : 91-96.
7. BEY P., CARRIE C., BECKENDORF V., GINESTET C., ALETTI P., MADELIS G., LUPORSI E., POMMIER P., COWEN D., GONZAGUE-CASABIANCA L., SIMONIAN-SAUVE M., MAIGON P., NAUDY S., LAGRANGE J.L., MARCIE S. : Dose escalation with 3D-CRT in prostate cancer : french study of dose escalation with conformal 3D radiotherapy in prostate cancer-preliminary results. Int. J. Radiat. Oncol. Biol. Phys. 2000 ; 48 : 513-517.
8. BEYER D.C., PRIESTLY J.B. : Biochemical disease free survival following I-125 prostate implantation. Int. J. Radial. Oncol. Biol. Phys. 1997 ; 37 : 559-563.
9. BLASKO J.C., RAGDE H., GRIMM P.D. : Transperineal ultrasound-guided implantation of the prostate : Morbidity and complications. Scand. J. Urol. Nephrol., 1991 ; 137 Suppl : 113-118.
10. BLASKO J.C., GRIMM P.D., RAGDE H. : Brachytherapy and organ preservetion in the management of carcinoma of the prostate. Semin. Radiat. Oncol., 1993 ; 3 : 240-249.
11. CHAIKIN D.C., BRODERICK G.A., MALLOY T.R., MALKOWICZ S.B., WHITTINGTON R., WEIN A.J. : Erectile dysfunction following minimally invasive treatments for prostate cancer. Urology, 1996 ; 48 : 100-104.
12. CHAPELON J.Y., MARGONARI J., THEILLÈRE Y., GORRY F., VERMIER F., BLANC E., GELET A. : Effects of high-energy focused ultrasound on kidney tissue in the rat and the dog. Eur. Urol., 1992 ; 22 : 147-152.
13. CHAPELON J.Y., MARGONARI J., VERMIER F., GORRY F., ECOCHARD R., GELET A. : In vivo effects of high intensity ultrasound on prostatic adenocarcinoma Dunning R3327. Cancer Res., 1992 ; 52 : 6353-6457.
14. CHAVRIER F., CHAPELON J.Y., GELET A., CATHIGNOL D. : Modeling of high-intensity focused ultrasound-induced lesions in the presence of cavitation bubbles. J. Acoust. Soc. Am., 2000 ; 108 : 432-440.
15. CHINN D.M., HOLLAND J., CROWNOVER R.L., ROACH M. III : Potency following high-dose three-dimensional conformal radiotherapy and the impact of prior major urologie surgical procedures in patients treated for prostate cancer. Int. J. Radial. Oncol. Biol. Phys., 1995 ; 33 : 15-22.
16. CHOU R.H., WILDER R.B., JI M., RYU J.K., LEIGH B.R., EARLE J.D., DUGGETT S., KUBO H.D., ROACH M. III, DEVERE WITHE R.W. : Acute toxicity of three-dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 47 : 115-119.
17. CROOK J., ESCHE B., FUTTER N. : Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function : the patient's perspective. Urology 1996 ; 47 : 387-394.
18. D'AMICO A.V., WHITTINGTON R., KAPLAN I., BEARD C., JIROUTEK M., MALKOWICZ B., WEIN A., COLEMAN N. : Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pre-treatment prostate specific antigen of > 4-20 ng/ml. Int. J. Radiat. Oncol. Biol. Phys., 1997 ; 37 : 1053-1058.
19. D'AMICO A.V., WHITTINGTON R., MALKOWICZ S.B., SCHULTZ D., BLANK K., BRODERICK G.A., TOMASZEWSKI J.E., RENSHAW A.A., KAPLAN I., BEARD C.J., WEIN A. : Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998 ; 280 : 969-974.
20. D'AMICO A. : Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology, 2001 ; 58 : 78-82.
21. FUKUNAGA-JOHNSON N., SANDLER H.M., MCLAUGHLIN P.W., STRAWDERMAN M.S., GRIJALVA K.H., KISH K.E., LICHTER A.S. : Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1997 ; 38 : 311-317.
22. GELBLUM D.Y., POTTERS L. : Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 48 : 119-124.
23. GELET A., CHAPELON J.Y., MARGONARI J., THEILLERE Y., GORRY F., SOUCHON R., BOUVIER R. : High intensity focused ultrasound : Experimentation on canine prostate. J. Endourol., 1993 ; 7 : 249-253.
24. GELET A., CHAPELON J.Y., MARGONARI J., THEILLERE Y., ET AL. : Treatment of Prostate Cancer with Transrectal Focused Ultrasound : Early Clinical Experience. Eur. Urol., 1996 ; 29 : 174-183.
25. HANKS G.E., SCHULTHEISS T.E., HUNT M.A., EPSTEIN B. : Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1995 ; 31 : 25-29.
26. HOLLISTER T.C., ZELEFSKY M.J., WOLFE T., RABEN A., WALLNER K. : Late toxicity of transperineal permanent 125 iodine implantation of the prostate for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1998 ; 42 (suppl 1) : 220.
27. JONLER M., RITTER M.A., BRINKMANN R., MESSING E.M., RHODES P.R., BRUSKEWITZ R.C. : Sequelae of definitive therapy for prostate cancer localized to the pelvis. Urology. 1994 ; 44 : 876-882.
28. JORDAN G.H., LYNCH D.F., WARDEN S.S., MCCRAW J.D., HOFFMAN G.C., SCHELLHAMMER P.F. : Major rectal complications following interstitial implantation of 125 iodine for carcinoma of the prostate. J. Urol., 1985 ; 134 : 1212-1214.
29. KAYE K.W., OLSON D.J., PAYNE J.T. : Detailed preliminary analysis of 125iodine implantation for localized prostate cancer using percutaneous approach. J. Urol., 1995 ; 153 : 1020-1025.
30. KOPER P.C.M., STROOM J.C., VAN PUTTEN W.L.J., KOREVAAR G.A., HEIJMEN B.J.M., WIJNMAALEN A., JANSEN P.P., HANSSENS P.E.J., GRIEP C., KROL A.D.G., SAMSON M.J., LEVENDAG P. : Acute morbidity reduction using 3DCRT for prostate carcinoma : a randomized study. Int. J. Radiat. Oncol. Biol. Phys., 1999 ; 43 : 727-734.
31. KUPELIAN P., KATCHER J., LEVIN H. ET AL. : External beam radiotherapy versus radical prostatectomy for clinical stage T1-T2 prostate cancer : Therapeutic implications of stratification by pretreatment PSA levels and biopsy gleason scores. Cancer J. Sci. Am., 1997 ; 3 : 78-87.
32. LAWTON C.A., WON M., PIPELICH M.V., ASBELL S.O., SHIPLEY W.U., HANKS G.E., COX J.D., PEREZ C.A. SAUGE W.T., DOGGETT S.R.L., RUBIN P. : Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate : Analysis of RTOG studies 7506 and 7706. Int. J. Radiat. Oncol. Biol. Phys., 1991 ; 21 : 935-936.
33. LEE W.R., HANKS G.E., HANLON A.L., SCHULTHEISS T.E., HUNT M.A. : Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy lor clinically localized prostate cancer : further evidence for a significant dose effect. Int. J. Radiat. Oncol. Biol. Phys., 1996 ; 35 : 251-257.
34. LILLEBY W., FOSSA S.D., WAEHRE H.R., OLSEN D.R. : Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys., 1999 ; 43 : 735-743.
35. LITWIN M.S., HAYS R.D., FINK A., GANZ P.A., LEAKE B., LEACH G.E., BROOK R.H. : Quality-of-life outcomes in men treated for localized prostate cancer. JAMA, 1995 ; 273 : 129-135.
36. LYONS J.A., KUPELIAN P.A., MOHAN D.S., REDDY C.A., KLEIN E.A. : Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology, 2000 ; 55 : 85-90.
37. MADALINSKA J.B., ESSINK-BOT M.L., DE KONING H.J., KIRKELS W.J., VAN DER MAAS P.J. : Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for sceen-detected or clinically diagnosed localized prostate cancer. J. Clin. Oncol., 2001 ; 19 : 1587-1588.
38. MANTZ C.A., SONG P., FARHANGI E., NAUTIYAL J., AWAN A., IGNACIO L., WEICHSELBAUM R., VIJAYAKUMAR S. : Potency probability followwing conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1997 ; 37 : 551-557.
39. MERRICK G.S., BUTLER W.M., DORSEY A.T., GALBREATH R.W., BLATT H., LIEF J.H. : Rectal function following prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 48 : 667-674.
40. NAG S., SCAPEROTH D.D., BADALAMENT R., HALL S.A., BURGERS J. : Transperineal palladium 103 prostate brachytherapy : analysis of morbidity and seed migration. Urology, 1995 ; 45 : 87-92.
41. NEULANDER E.Z., DUNCAN R.C., TIGUERT R., POSEY J.T., SOLOWAY M.S. : Deffered treatment of localised prostate cancer in ederly ; the impact of th age and the stage at the time of diagnosis on treatment decision. Br. J. Urol., 85 : 699-704.
42. NGUYEN L.N., POLLACK A., ZAGARS G.K. : Late effects after radiotherapy for prostate cancer in a randomized dose-response study : results of a self-assessment questionnaire. Urology, 1998 ; 51 : 991-997.
43. PEARSON J.D., CARTER H.B. : Natural history of changes in prostate specific antigen in early stage prostate cancer. J. Urol., 1994 ; 152 : 1743-1747.
44. PEREZ C.A., LEE H.K., ANASATASIOS G., LOCKETT M.A. : Technical factors affecting morbidity in definitive irradiation for localized carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys., 1994 ; 28 : 811-819.
45. PIPELICH M.V., KRALL J.M., SAUCE W.T., JOHNSON R.J., RUSS H.H., HANKS G.E., PEREZ C.A., ZINNINGER M., MARTZ K.L., GARDNER P. : Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate-analysis of RTOG study 75-06. Int. J. Radiat. Oncol. Biol. Phys., 1987 ; 13 : 351-357.
46. PISANSKY T.M., KAHN M.J., BOSTWICK D.G. : An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer, 1997 ; 79 : 2154-2161.
47. POLLACK A., ZAGARS G.K., STARKSCHALL G., CHILDRESS C.H., KOPPLIN S., BOYER A.L., ROSEN I.I. : Conventionas vs. Conformal radiotherapy for prostate cancer : preliminary results of dosimetry and acute toxicity. Int. J. Radiat. Oncol. Biol. Phys., 1996 ; 34 : 555-564.
48. POTOSKY A.L., LEGLER J., ALBERTSEN P.C., STANFORD J.L., GILLILAND F.D., HAMILTON A.S., ELEY J.W., HARLAN L.C. : Health outcomes after prostatectomy or radiotherapy for prostate cancer : results from the Prostate Cancer Outcomes Study. J. Natl. Cancer Inst., 2000 ; 92 : 1582-1592.
49. POTTERS L., CHA C., OSHINSKY G., VENKATRAMAN E., ELEFSKY M., LEIBEL S. : Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J. Sci. Am., 1999 ; 5 : 301-306.
50. PRESTIDGE B.R., HOAK D.C., GRIMM P.D., RAGDE H., CAVANAGH W., BLASKO J.C. : Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1997 ; 37 : 31-39.
51. RAGDE H., ELGAMAL A.A., SNOW P.B., BRANDT J., BARTOLUCCI A.A., NADIR B.S., KORB L.J. : Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer, 1998 ; 83 : 989-1001.
52. RAGDE H., BLASKO J.C., GRIMM P.D., KENNY G.M., SYLVESTER J.E., HOAK D.C., LANDIN K., CAVANAGH W. : Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer, 1997 ; 80 : 442-453.
53. ROACH M. III, CHINN D.M., HOLLAND J., CLARKE M. : A pilot survey of sexual function and quality of life following 3D conformal radiotherapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1996 ; 35 : 869-874.
54. ROUVIÈRE O., LYONNET D., RAUDRANT A., COLIN-PANGAUD C., CHAPELON J.Y., BOUVIER R., DUBERNARD J.M., GELET A. : MRI Appearance of prostate following Transrectal HIFU ablation of localized cancer. Eur. Urol. 2001 ; 40 : 265-274.
55. SANDLER H.M., MCLAUGHLIN P.W., TEN HAKEN R.K., ADDISON H., FORMAN J., LICHTER A. : Three dimensional conformal radiotherapy for the treatment of prostate cancer : low risk of chronic rectal morbidity observed in a large series of patients. Int. J. Radiat. Oncol. Biol. Phys., 1995 ; 33 : 797-801.
56. SCHULTHEISS T.E., LEE W.R., HUNT M.A., HANLON A.L., PETER R.S., HANKS G.E. : Late GI and GU complications in the treatment of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1997 ; 37 : 3-11.
57. SHARKEY J., CHOVNICK S.D., BEHAR RJ., PEREZ R., OTHEGUY J., SOLC Z., HUFF W., CANTOR A. : Outpatient ultrasound-guded palladium 103 brachytherapy for localized adenocarcinoma of the prostate : a preliminary report of 434 patients. Urology 1998 ; 5 : 796-803.
58. SHIPLEY W.U., PROUT G.R. JR., COACHMAN N.M., MCMANUS P.L., HEALEY E.A., ALTHAUSEN A.F., HENEY N.M., PARKHURST E.C., YOUNG H.H. II, SHIPLEY J.W., KAUFMAN S.D. : Radiation therapy for localized prostate carcinoma : Experience at the Massachusetts General Hospital (1973-1981). Natl. Cancer. Inst. Monogr. 1988 ; 7 : 67-73.
59. STOCK R.G., STONE N.N. : The effect of pronostic factors on therapeutic outcome following transperineal prostate brachytherapy. Sem. Surg. Oncol., 1997 ; 13 : 454-460.
60. STOCK R.G., STONE N.N., KAO J., IANNUZZI C., UNGER P. : The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy. Cancer, 2000 ; 89 : 1829-1834.
61. STOCK R.G., STONE N.N., DEWYNGAERT J.K., LAVAGNINI P., UNGER P.D. : Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer, 1996 ; 77 : 2386-2392.
62. STOCK R.G., STONE N.N., IANNUZZI C. : Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1996 ; 35 : 267-272.
63. STOKES S.H. : Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 47 : 129-136.
64. TALCOTT J.A., CLARK J.C., STARK P. ET AL. : Long-term treatment-related complications of brachytherapy for early prostate cancer: A survey of treated patients. Proceedings of ASCO, 1999 ; 18 : 311a.
65. TALCOTT J.A., CLARK J.A., STARK P.C., MITCHELL S.P. : Long-term treatment related complications of brachytherapy for early prostate cancer : a survey of patients previously treated. J. Urol., 2001 ; 166 : 494-499.
66. TALCOTT J.A., RIEKER P., PROPERT K.J., CLARK J., KAUTOFF P., BEARD C., KAPLAN I., LOUGHLIN K., RICHIE J., WISHNOW K. : Long-term complications of treatment for early prostate cancer : 2-year follow-up in a prospective multi-institutional outcomes study : Proceedings of the 32nd meeting of ASCO. J. Clin. Oncol., 1996 ; 15 : 252 (Abstr).
67. TALCOTT J.A., RIEKER P., CLARK J.A., PROPERT K.J., WEEKS J.C., BEARD C.J., WISHNOW K.I., KAPLAN I., LOUGHLIN K.R., RICHIE J.P., AND KANTOFF P. : Patient-reported syptoms after primary therapy for early prostate cancer : Results of a prospective cohort study. J. Clin. Oncol., 1998 ; 16 : 275-283.
68. THEODORESCU D., GILLENWATER J.Y., KOUTOUVELIS PG. : Prostatourethral- rectal fistula after prostate brachytherapy. Cancer. 2000 ; 89 : 2085-2091.
69. WALLNER K., ROY J., HARRISON L. : Dosimetry guidelines to minimize uretrhal and rectal morbidity following transperineal 1-125 prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys., 1995 ; 32 : 465-471.
70. WALLNER K., LEE H., WASSERMAN S., DATTOLI M. : Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int. J. Radiat. Oncol. Biol. Phys., 1997 ; 37 : 565-569.
71. WALLNER K., ROY J., ZELEFSKY M., FUKS Z., HARRISON L. : Short-term freedom from disease progression after 1-125 prostate implantation. Int. J. Radiat. Oncol. Biol. Phys., 1994 ; 30 : 405-409.
72. WALLNER K., ROY J., HARRISON L. : Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J. Clin. Oncol., 1996 ; 14 : 449-453.
73. WILDER R.B., CHOU R.H., RYU J.K., STERN R.L., WONG M.S., J.I. M., ROACH M. III, DEVERE WITHE R. : Potency preservation after three-dimensional conformal radiotherapy for prostate cancer. Am. J. Clin. Oncol., 2000 ; 23 : 330-333.
74. ZELEPSKY M.J., WALLNER K.E., LING C.C., RABEN A., HOLLISTER T., WOLFE T., GRANN A., GAUDIN P., FUKS Z., LEIBEL S.A. : Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J. Clin. Oncol., 1999 ; 17 : 517-522.
75. ZELEFSKY M.J., HOLLISTER T., RABEN A., MATTHEWS S., WALLNER K.E. : Five-year biochemical outcome and toxicity with transperineal CT-planned permanent 1-125 prostate implantation for patients with localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 47 : 1261-1266.
76. ZELEFSKY M.J., COWEN D., FUKS Z., SHIKE M., BURMAN C., JACKSON A., VENKATRAMEN E.S., LEIBEL S.A. : Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer, 1999 ; 85 : 2460-2468.